Investigators have shown that afatinib may be a promising treatment for overcoming ceritinib resistance in ALK-positive NSCLC cells by inhibiting the EGFR162 and neuroregulatory protein (NRG1) signaling180 pathways. The gene discussed is ALK; the disease is non-small cell lung carcinoma.